(Q33652861)

28 July 2017

1 reference

title

Tamoxifen and contralateral breast cancer (English)

1 reference

28 July 2017

1 reference

2

Jordan VC

1 reference

28 July 2017

O'Regan R

1

1 reference

PubMed ID

10359362

28 July 2017

Gradishar WJ

series ordinal

3

1 reference

28 July 2017

1 June 1999

1 reference

Journal of the American College of Surgeons

28 July 2017

1 reference

28 July 2017

188

1 reference

28 July 2017

6

1 reference

28 July 2017

678-683

1 reference

28 July 2017

Cancer statistics, 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Potential role of tamoxifen in prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Preliminary Results From the Cancer Research Campaign Trial Evaluating Tamoxifen Duration in Women Aged Fifty Years or Older With Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. International Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

The relationship of cancer of the female breast to artificial menopause and martial status

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Effect of an estrogen antagonist (tamoxifen) on the initiation and progression of gamma-irradiation-induced mammary tumors in female Sprague-Dawley rats

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Anti-oestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OUJ mice

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

The relationship between estrogen receptors in primary and secondary breast carcinomas and in sequential primary breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2899%2900057-5

7 January 2021

10.1016/S1072-7515(99)00057-5

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10359362